Anthropic Adds Novartis CEO Vas Narasimhan to Its Board, and That’s a Big Deal

Anthropic just made a board appointment that actually makes sense if you think about where AI is headed.

Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining Anthropic’s Board of Directors. He was appointed by the Anthropic Long-Term Benefit Trust — that independent body with no financial stake in the company that’s supposed to keep Anthropic honest about balancing profit with its public benefit mission.

Narasimhan isn’t your typical tech board hire. The guy has overseen the development and approval of more than 35 novel medicines. That’s not nothing. As Daniela Amodei put it, “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.”

She’s right. The pharmaceutical industry is one of the most regulated on the planet — for good reason. If you can navigate FDA approvals, global health regulations, and the ethical landmines of bringing new drugs to market, you probably have something useful to say about deploying AI responsibly.

Here’s the part I find interesting: with Narasimhan’s appointment, Trust-appointed directors now make up a majority of the board. That’s a structural shift worth noting. The Long-Term Benefit Trust was designed precisely for moments like this — to ensure that as Anthropic grows (and it is growing fast), the company doesn’t drift away from its founding mission of developing AI for the long-term benefit of humanity.

Narasimhan’s background in global health is also relevant here. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine and serves on the Council on Foreign Relations. This isn’t someone who’s just been sitting in a corner office.

“Working across medicine, innovation, and global health has shown me the transformative potential of technology when deployed responsibly,” Narasimhan said. “In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines.”

He joins a board that already includes Dario and Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. It’s a mix of founders, investors, and operators. Narasimhan brings something different — deep experience in a heavily regulated industry where getting it wrong has literal life-or-death consequences.

I’ve been watching how AI companies handle governance, and most of them don’t handle it well. They stack boards with people who think like them and then wonder why they make the same mistakes. Anthropic’s approach with the Long-Term Benefit Trust is unusual, and appointments like this suggest they’re actually taking the “benefit” part seriously.

The healthcare angle is particularly smart. AI in drug discovery and clinical decision-making is one of those areas where the hype might actually be justified. Having someone who’s been through the trenches of drug development on the board isn’t just good optics — it’s practical.

Whether this translates into better product decisions or just better press releases remains to be seen. But I’ll take a board with a Novartis CEO who’s actually developed medicines over another AI startup board full of former bankers any day.